204863-53-6

Basic information

• Product Name: 4-(4-OXO-PIPERIDINE-1-CARBONYL)-BENZAMIDE
• Synonyms: ETHYL 3,4-DIHYDRO-3-OXO-2H-BENZO[B][1,4]THIAZINE-6-CARBOXYLATE;3-OXO-3,4-DIHYDRO-2H-BENZO[1,4]THIAZINE-6-CARBOXYLIC ACID ETHYL ESTER;4-(4-OXO-PIPERIDINE-1-CARBONYL)-BENZAMIDE;2H-1,4-Benzothiazine-6-carboxylic acid, 3,4-dihydro-3-oxo-, ethyl ester;3-keto-4H-1,4-benzothiazine-6-carboxylic acid ethyl ester;3-oxo-4H-1,4-benzothiazine-6-carboxylic acid ethyl ester;ethyl 3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-carboxylate;ethyl 3-oxo-4H-1,4-benzothiazine-6-carboxylate
• CAS NO: 204863-53-6
• Molecular Formula: C₁₁H₁₁NO₃S
• Molecular Weight: 246.26
• Mol File: 204863-53-6.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(4-OXO-PIPERIDINE-1-CARBONYL)-BENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-OXO-PIPERIDINE-1-CARBONYL)-BENZAMIDE(204863-53-6)
• EPA Substance Registry System: 4-(4-OXO-PIPERIDINE-1-CARBONYL)-BENZAMIDE(204863-53-6)

Safety Data

• Hazard Codes: Xi
• Statements: 43
• Safety Statements: 36/37
• Hazardous Substances Data: 204863-53-6(Hazardous Substances Data)

Usage

General Description

4-(4-OXO-PIPERIDINE-1-CARBONYL)-BENZAMIDE is a chemical compound with the molecular formula C15H17N3O3. It is a benzamide derivative with a piperidine-1-carbonyl group attached to the benzene ring. 4-(4-OXO-PIPERIDINE-1-CARBONYL)-BENZAMIDE is often used in pharmaceutical research as a building block in the synthesis of various biologically active molecules. It has also been studied for its potential pharmacological properties, including its potential as a drug for the treatment of certain diseases. The compound's structure and properties make it a valuable tool in the development of new drugs and in the study of biological systems.

Upstream product

• 16588-16-2 ethyl 4-chloro-3-nitrobenzoate 
• 367-80-6 ethyl 4-fluoro-3-nitrobenzoate 
• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 96-99-1 4-chloro-3-nitrobenzoate 
• 204863-51-4 4-ethoxycarbonylmethylsulfanyl-3-nitrobenzoic acid 
• 204863-52-5 ethyl 4-ethoxycarbonylmethylsulfanyl-3-nitrobenzoate 

Downstream Products

• 272437-84-0 3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxylic acid 
• 1392139-27-3 (Z)-2-(2-methylbenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxylic acid 
• 1392139-28-4 (Z)-2-(2-methoxybenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxylic acid 
• 1392139-45-5 C₂₄H₂₇N₃O₂S 
• 1392139-46-6 C₂₄H₂₇N₃O₃S 

Relevant articles and documents

Discovery of a Plasmodium falciparum Glucose-6-phosphate Dehydrogenase 6-phosphogluconolactonase Inhibitor (R,Z)-N-((1-Ethylpyrrolidin-2-yl)methyl)-2- (2-fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxamide (ML276) that reduces parasite growth in vitro

A high-throughput screen of the NIH's MLSMR collection of ～340000 compounds was undertaken to identify compounds that inhibit Plasmodium falciparum glucose-6-phosphate dehydrogenase (Pf G6PD). PfG6PD is important for proliferating and propagating P. falciparum and differs structurally and mechanistically from the human orthologue. The reaction catalyzed by glucose-6-phosphate dehydrogenase (G6PD) is the first, rate-limiting step in the pentose phosphate pathway (PPP), a key metabolic pathway sustaining anabolic needs in reductive equivalents and synthetic materials in fast-growing cells. In P. falciparum, the bifunctional enzyme glucose-6-phosphate dehydrogenase-6- phosphogluconolactonase (Pf GluPho) catalyzes the first two steps of the PPP. Because P. falciparum and infected host red blood cells rely on accelerated glucose flux, they depend on the G6PD activity of PfGluPho. The lead compound identified from this effort, (R,Z)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-(2- fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carbox-amide, 11 (ML276), is a submicromolar inhibitor of PfG6PD (IC50 = 889 nM). It is completely selective for the enzyme's human isoform, displays micromolar potency (IC50 = 2.6 μM) against P. falciparum in culture, and has good drug-like properties, including high solubility and moderate microsomal stability. Studies testing the potential advantage of inhibiting Pf G6PD in vivo are in progress.

AMINE COMPOUNDS

The present invention provide a compound of the formula:wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.

Quantitative structure-activity relationship study of N-(3-oxo-3,4- dihydro-2H-benzol[1,4]thiazine-6-carbonyl)guanidines as potent na/h exchange inhibitors

We have previously reported that N-(4-isopropyl-2,2-dimethyl-3-oxo-3,4- dihydro-2H-benzo[1,4]oxazine-6carbonyl)guanidine (4b) methanesulfonate salt (KB-R9032) is a potent and highly water-soluble Na/H exchange inhibitor. In a series of studies on Na/H exc